PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRO-1107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRO-1107 overview
PRO-1107 is under development for the treatment of solid tumors, epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, esophageal squamous cell carcinoma, urothelial cancers including bladder cancer, ureter cancer and renal cancer. The drug candidate is an antibody drug conjugate (ADC), administered through intravenous route. It acts by targeting Protein Tyrosine Kinase 7 (PTK7).
ProfoundBio Suzhou overview
ProfoundBio Suzhou (ProfoundBio) discovers and develops antibody-drug conjugates and T-cell engagers for the treatment of cancer. The company is investigating PRO1184, a FOLR1 (folate receptor alpha) based antibody targeting solid tumors; and PRO1160 to treat renal cell cancer (RCC) and non-Hodgkin lymphoma (NHL) cancer. It is also evaluating PRO1107, PRO1109, PRO1135, PRO1173, PRO1103, PRO1106 and PRO1176 programs against solid tumors. The company focuses on developing drugs that deliver small molecule payloads to tumor cells and eradicate cancer by supporting the immune system. ProfoundBio is headquartered in Suzhou, Jiangsu, China.
For a complete picture of PRO-1107’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
